RO 📈 Roche Holding - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012032113
RO: Medicines, Diagnostic Tests, Instruments, Digital Health Solutions
Roch Holding AG operates as a multinational healthcare company, with a presence in numerous regions, including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company's pharmaceutical division develops and markets a wide range of products, focusing on therapeutic areas such as anemia, oncology - including blood and solid tumors, dermatology, hemophilia, and inflammatory and autoimmune diseases. Additionally, it offers treatments for neurological disorders, ophthalmology, respiratory disorders, and transplantation. The company's product portfolio is constantly evolving, with various products in development for different therapeutic areas.
Roche Holding AG also has a significant diagnostics business, providing in vitro tests for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other conditions. The company's diagnostic instruments and digital health solutions enable healthcare professionals to make informed decisions and provide effective patient care. Furthermore, Roche has established strategic partnerships, such as its collaboration with Flare Therapeutics Inc., which leverages proteomic and mass spectrometry platforms to discover novel small molecules targeting transcription factor targets in oncology. This collaboration underscores the company's commitment to innovation and its pursuit of groundbreaking treatments.
With a rich history dating back to 1896, Roche Holding AG is headquartered in Basel, Switzerland, and has established itself as a leading player in the global pharmaceutical and diagnostics industries. The company's common stock is listed under the ISIN CH0012032113, and it is classified under the GICS Sub Industry: Pharmaceuticals. As a major healthcare company, Roche Holding AG continues to drive innovation, investing in research and development to address some of the world's most pressing healthcare challenges. For more information, please visit the company's website at https://www.roche.com.
Additional Sources for RO Stock
RO Stock Overview
| Market Cap in USD | 232,460m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
RO Stock Ratings
| Growth 5y | 3.31% |
| Fundamental | 61.5% |
| Dividend | 59.7% |
| Rel. Strength Industry | 52.3 |
| Analysts | - |
| Fair Price Momentum | 255.21 CHF |
| Fair Price DCF | 4262.74 CHF |
RO Dividends
| Dividend Yield 12m | 3.63% |
| Yield on Cost 5y | 3.65% |
| Annual Growth 5y | 1.77% |
| Payout Consistency | 100.0% |
RO Growth Ratios
| Growth Correlation 3m | -70.7% |
| Growth Correlation 12m | 69.6% |
| Growth Correlation 5y | -24.7% |
| CAGR 5y | 0.14% |
| CAGR/Mean DD 5y | 0.01 |
| Sharpe Ratio 12m | 0.15 |
| Alpha | -5.25 |
| Beta | 0.28 |
| Volatility | 19.89% |
| Current Volume | 22.3k |
| Average Volume 20d | 29.7k |
As of December 26, 2024, the stock is trading at CHF 264.60 with a total of 22,296 shares traded.
Over the past week, the price has changed by -2.29%, over one month by -3.15%, over three months by -8.76% and over the past year by +5.68%.
Yes, based on ValueRay Fundamental Analyses, Roche Holding (SW:RO) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 61.54 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RO as of December 2024 is 255.21. This means that RO is currently overvalued and has a potential downside of -3.55%.
Roche Holding has no consensus analysts rating.
According to ValueRays Forecast Model, RO Roche Holding will be worth about 276.2 in December 2025. The stock is currently trading at 264.60. This means that the stock has a potential upside of +4.39%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 286 | 8.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 276.2 | 4.4% |